MedTrace Logo

Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer

NCT02981524 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2021-02-10

Study results available
· View outcomes & findings →

Summary

This study will be looking at the objective response rate (ORR) as measured by RECIST in in patients with mismatch repair-proficient (MMR-p), advanced colorectal cancer that treated with CY/GVAX in combination with Pembrolizumab.

Conditions

Interventions

DRUG

CY

CY is administered intravenously at 200 mg/m2

BIOLOGICAL

GVAX

GVAX is administered intradermally at 5E8 colon cancer cells + 5E7 GM-CSF secreting

DRUG

Pembrolizumab

Pembrolizumab is administered intravenously at 200 mg

Sponsors & Collaborators

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    lead OTHER

Principal Investigators

  • Nilofer Azad, MD · The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-26
Primary Completion
2018-03-20
Completion
2018-03-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02981524 on ClinicalTrials.gov